Finance

Healthcare Stocks Touched New Lows: Biocept Inc (NASDAQ:BIOC), Aquinox Pharmaceuticals (NASDAQ:AQXP), Galmed Pharmaceuticals (NASDAQ:GLMD), Egalet (NASDAQ:EGLT)

Shares of many of the biotech and pharmaceutical companies that went public earlier this year are now trading well below the offer price, including Biocept Inc (NASDAQ:BIOC), uniCure and Galmed Pharmaceuticals. Biocept Inc (NASDAQ:BIOC) stock performance was -4.99% in last session and finished the day at $4.95. Traded volume was 12,421.00million shares in the last session and the average volume of the stock remained 44.22K shares. Biocept Inc (NASDAQ:BIOC) insider ownership is 0.40%.

Research analysts at Canaccord Genuity initiated coverage on shares of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) in a report released on Wednesday. Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) dropped -1.47 percent to $8.72 Thursday on volume of 15,558.00million shares. The intra-day range of the stock was $8.72 to $9.00. Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) has a market capitalization of $93.09million.

Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) has seen a massive down tick in the past few trading sessions, and it believe that this downward trajectory might continue for the stock and may lead it to lower levels. Short term traders can short the stock at current levels with a tight stop loss at $11 for targets of $8 or lower. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)’s stock on Apr 17, 2014 reported a decrease of -3.49% to the closing price of $3.58. Its fifty two weeks range is $8.58 -$9.30. The total market capitalization recorded $91.59million. The overall volume in the last trading session was 29,805.00million shares. In its share capital, GLMD has 10.19million outstanding shares.

“Egalet Corporation (NASDAQ:EGLT) is a specialty pharmaceutical company developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and other indications. We have created two distinct drug delivery systems, each with novel abuse-deterrent features and the ability to control the release profile of the active pharmaceutical ingredient (API): said by Egalet Corporation (NASDAQ:EGLT)’s chief executive Bob Radie in an interveiw. On Thursday, shares of Egalet Corp (NASDAQ:EGLT) dropped -3.15% to close the day at $9.84. Company return on investment (ROI) is 46.90% and its monthly performance is recorded as -43.84%.